10 Key Insights into Akeso's Ivonescimab and Its ASCO Plenary Spotlight

As the annual meeting of the American Society of Clinical Oncology (ASCO) approaches, the biotech world is buzzing with anticipation—and speculation. At the center of this whirlwind is Akeso and Summit Therapeutics' investigational drug, ivonescimab, which has earned a coveted plenary slot. The spotlight shines on survival data that have been cloaked in mystery, leaving analysts and investors eager for clarity. This listicle unpacks the ten most critical aspects of ivonescimab's journey to the plenary stage, from its mechanism of action to the implications of its potential success. Whether you're a seasoned investor or a curious observer, these insights will help you navigate the narratives shaping this year's ASCO.

1. The Drug at the Center: Ivonescimab

Ivonescimab (formerly AK112) is a bispecific antibody that simultaneously targets PD-1 and VEGF—two key pathways in cancer growth and immune evasion. Developed by Akeso and licensed to Summit Therapeutics for ex-China rights, this drug is designed to overcome resistance seen with traditional PD-1 inhibitors. The plenary presentation at ASCO will showcase survival data from a Phase II/III trial in non-small cell lung cancer (NSCLC), specifically in patients who have progressed on prior therapies. If positive, ivonescimab could become a new standard in second-line NSCLC treatment. However, the exact magnitude of the benefit remains tightly guarded, fueling both hope and skepticism among experts. Next item

2. What the Plenary Slot Signifies

A plenary presentation at ASCO is the pinnacle of recognition for clinical data; it indicates that the results are considered highly impactful by the review committee. For Akeso and Summit, this slot is both a validation of ivonescimab's potential and a high-stakes platform. Historically, plenary data have dramatically shifted stock prices and treatment paradigms. The selection suggests that the survival benefit observed in the trial is statistically significant and clinically meaningful—but without seeing the numbers, the market is left guessing. Investors are particularly attuned to whether the data will show a survival benefit comparable to or exceeding that of current therapies like chemotherapy, immunotherapy, or targeted agents. Next item

3. The Mystery Around the Survival Data

Despite the plenary announcement, detailed survival results—such as median overall survival (OS) and progression-free survival (PFS)—have not been publicly disclosed. This opacity has created a vacuum of speculation. Akeso has shared only top-line positive efficacy and safety, leaving experts to parse clues from prior presentations and trial design. The lack of transparency is not unusual before major medical meetings, but the combination of a plenary spot and incomplete data amplifies the intrigue. Some analysts fear the data might show only a modest benefit in a highly specific patient subgroup, while others believe the company is holding back a blockbuster result. Either way, the ASCO presentation will settle the debate. Next item

4. The Trial Design: A Closer Look

The pivotal trial for ivonescimab is a randomized, double-blind, Phase II/III study comparing ivonescimab to docetaxel (standard chemotherapy) in patients with advanced NSCLC who have progressed after platinum-based therapy and a PD-1/PD-L1 inhibitor. The primary endpoints are OS and PFS, with secondary endpoints including objective response rate and durability. Notably, the trial included patients with both squamous and non-squamous histologies, broadening the potential label. The study's design also allows for crossover upon progression, which could confound survival analysis. Understanding these nuances is crucial for interpreting the final data, as they will affect the drug's regulatory path and commercial potential. Next item

5. Comparison to Existing Therapies

Current second-line options for NSCLC after checkpoint inhibitor failure are limited and modest. Docetaxel provides a median OS of around 8-9 months, and combinations with ramucirumab or nintedanib add only a few weeks. Immunotherapy rechallenge is rarely effective. Ivonescimab's dual mechanism offers a theoretical advantage: by blocking PD-1 and VEGF simultaneously, it may reinvigorate exhausted T-cells while normalizing tumor vasculature. If the plenary data show a hazard ratio for OS below 0.70 or a median benefit of several months, that would represent a meaningful advance. However, comparisons must account for patient populations; if the trial enrolled healthier patients, the absolute numbers might look better than they are. Next item

6. Regulatory and Commercial Implications

Positive survival data could pave the way for accelerated or full approvals in the US and China. Akeso has already submitted a Biologics License Application (BLA) in China for first-line NSCLC, but the second-line data from this trial would expand the addressable market. For Summit Therapeutics, which holds rights in the US, Europe, Japan, and other key regions, the potential is enormous. The global NSCLC second-line market is estimated at over $5 billion annually. If ivonescimab demonstrates best-in-class efficacy with manageable safety, it could capture a significant share. Conversely, a marginal benefit might limit its use to niche populations and require competitive pricing. The ASCO data will heavily influence partnership deals, licensing terms, and future investment. Next item

7. The Role of Biomarkers and Patient Selection

One of the unanswered questions is whether ivonescimab's benefit is enriched in certain biomarker-defined subgroups. For instance, patients with high PD-L1 expression or specific VEGF-related gene signatures might respond better. The trial did not mandate biomarker selection, but exploratory analyses could be presented at ASCO. If the survival benefit is mostly driven by a subset, the drug's commercial value might be narrower but still significant if the subset is large. Additionally, the company might develop companion diagnostics to guide use. Analysts will scrutinize forest plots and subgroup analyses to gauge the drug's real-world applicability. Next item

8. Safety Profile and Tolerability

Combining PD-1 and VEGF inhibition raises concerns about additive toxicities such as hypertension, proteinuria, bleeding, and immune-related adverse events (irAEs). Early data from earlier-stage trials presented at previous meetings showed a safety profile similar to other anti-PD-1/VEGF combinations like Keytruda plus Avastin, with manageable rates of grade 3+ events. However, the longer exposure in the Phase II/III trial could reveal new signals. The ASCO presentation will likely include a safety summary. If the tolerability is acceptable, it would support use in a broader patient population, including those with comorbidities. A poor safety profile, on the other hand, could limit adoption despite efficacy. Next item

9. Competitive Landscape and Pipeline Positioning

Ivonescimab faces competition from other bispecifics (e.g., KN046 from Alphamab, bintrafusp alfa from Merck/Pfizer) and from novel ADCs, KRAS inhibitors, and cellular therapies. However, none have yet achieved a survival benefit in post-checkpoint NSCLC. If ivonescimab succeeds, it could establish a new class of dual-targeting antibodies. The drug also has potential in other indications; Akeso is investigating it in several solid tumors, including colorectal and cervical cancers. The ASCO plenary data will therefore not only affect the stock but also influence the entire bispecific antibody field. Next item

10. Wall Street Sentiment and Stock Price Implications

Leading up to ASCO, shares of both Akeso (Hong Kong listed) and Summit (NASDAQ: SMMT) have been volatile on rumors and analyst reports. Some hedge funds have taken large positions betting on positive data. The plenary announcement itself caused a modest rally, but the true catalyst will be the actual numbers. With options and derivatives activity increasing, the event is seen as binary: a home run could double or triple some stocks, while a disappointment might lead to significant drops. Investors should also watch for the press release timing—often the data are released early on the day of the presentation. Careful reading of the abstract, if released beforehand, can provide clues, but the full presentation is the final word. Back to top

In conclusion, Akeso's ivonescimab plenary spot at ASCO 2025 is a watershed moment for the bispecific antibody class and for lung cancer treatment. The survival data, once unveiled, will either confirm the drug's promise or deflate the hype. Investors, clinicians, and patients alike should prepare for a detailed presentation that will clarify the drug's place in the evolving landscape. Whether you're rooting for a breakthrough or cautious about the unknowns, these ten insights provide the context needed to understand the stakes. The countdown to ASCO has begun.